CIBC Asset Management
SRPT icon

CIBC Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

CIBC Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,851
Closed -$347K – 1240
2024
Q4 		$347K Buy
2,851
+139
+5% +$17K ﹤0.01% 831
2024
Q3 		$339K Buy
2,712
+86
+3% +$11.9K ﹤0.01% 839
2024
Q2 		$415K Buy
2,626
+316
+14% +$40.6K ﹤0.01% 762
2024
Q1 		$299K Hold
2,310
– – ﹤0.01% 835
2023
Q4 		$223K Hold
2,310
– – ﹤0.01% 936
2023
Q3 		$280K Hold
2,310
– – ﹤0.01% 815
2023
Q2 		$265K Hold
2,310
– – ﹤0.01% 844
2023
Q1 		$318K Buy
2,310
+49
+2% +$6.36K ﹤0.01% 790
2022
Q4 		$293K Sell
2,261
-124,714
-98% -$14.5M ﹤0.01% 823
2022
Q3 		$14M Buy
126,975
+123,961
+4,113% +$12.5M 0.06% 176
2022
Q2 		$226K Sell
3,014
-193,955
-98% -$14.3M ﹤0.01% 1033
2022
Q1 		$15.4M Hold
196,969
– – 0.05% 186
2021
Q4 		$17.7M Sell
196,969
-108,162
-35% -$9.25M 0.06% 170
2021
Q3 		$28.2M Buy
305,131
+30,751
+11% +$2.37M 0.11% 126
2021
Q2 		$21.3M Buy
274,380
+271,466
+9,316% +$20.6M 0.09% 139
2021
Q1 		$217K Buy
2,914
+118
+4% +$10.9K ﹤0.01% 1191
2020
Q4 		$477K Hold
2,796
– – ﹤0.01% 761
2020
Q3 		$393K Buy
2,796
+69
+3% +$10.5K ﹤0.01% 754
2020
Q2 		$437K Hold
2,727
– – ﹤0.01% 712
2020
Q1 		$267K Hold
2,727
– – ﹤0.01% 769
2019
Q4 		$352K Buy
+2,727
New +$275K ﹤0.01% 814
2019
Q3 		– Sell
-2,317
Closed -$352K – 1152
2019
Q2 		$352K Hold
2,317
– – ﹤0.01% 800
2019
Q1 		$276K Hold
2,317
– – ﹤0.01% 870
2018
Q4 		$253K Hold
2,317
– – ﹤0.01% 840
2018
Q3 		$374K Hold
2,317
– – ﹤0.01% 782
2018
Q2 		$306K Buy
+2,317
New +$219K ﹤0.01% 822

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

CIBC Asset Management's SRPT Position: Q1 2025 in Review

CIBC Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,851 shares — an estimated $347K sold.

CIBC Asset Management first reported a position in SRPT in Q2 2018 and held it in 26 quarters. The position peaked at $28.2M in Q3 2021. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • CIBC Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • CIBC Asset Management sold 2,851 Sarepta Therapeutics shares in Q1 2025, an estimated $347K.
  • CIBC Asset Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 26 quarters.
  • CIBC Asset Management's Sarepta Therapeutics position peaked at $28.2M in Q3 2021.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on CIBC Asset Management's 13F filing for Q1 2025, filed 13 May 2025.